From Nuclear Winter to Renewal: Biotech Investing for 2026
Podcast: BioSpacePublished On: Thu Jan 08 2026
Description: In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsMaha Katabi, General Partner, Sofinnova InvestmentsAndrew Lam, Managing Director, Head of Biotech Private Equity, Ally Bridge Group (ABG)Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
The note was deleted
The note was saved
Your message was sent